Silence Therapeutics plc (NASDAQ:SLN) Receives Average Rating of "Moderate Buy" from Analysts

Shares of Silence Therapeutics plc (NASDAQ:SLN - Get Free Report) have received a consensus rating of "Moderate Buy" from the seven ratings firms that are currently covering the firm, MarketBeat reports. One research analyst has rated the stock with a sell recommendation and six have assigned a buy recommendation to the company. The average 12-month price objective among brokers that have updated their coverage on the stock in the last year is $33.83.

A number of equities research analysts have issued reports on SLN shares. BMO Capital Markets cut their price target on shares of Silence Therapeutics from $67.00 to $25.00 and set an "outperform" rating on the stock in a report on Tuesday, March 4th. Morgan Stanley cut their target price on Silence Therapeutics from $45.00 to $25.00 and set an "overweight" rating on the stock in a research note on Friday, May 9th. Chardan Capital lowered their price target on Silence Therapeutics from $55.00 to $35.00 and set a "buy" rating for the company in a research report on Friday, May 9th. The Goldman Sachs Group dropped their price objective on Silence Therapeutics from $4.00 to $3.00 and set a "sell" rating for the company in a report on Friday, May 9th. Finally, HC Wainwright reissued a "buy" rating and set a $75.00 target price on shares of Silence Therapeutics in a research note on Friday, March 7th.

Institutional Trading of Silence Therapeutics

Hedge funds have recently modified their holdings of the business. Commonwealth of Pennsylvania Public School Empls Retrmt SYS purchased a new stake in shares of Silence Therapeutics in the fourth quarter valued at about $134,000. JPMorgan Chase & Co. purchased a new stake in Silence Therapeutics in the 4th quarter valued at approximately $26,000. Trexquant Investment LP purchased a new stake in Silence Therapeutics in the 4th quarter valued at approximately $438,000. Barclays PLC grew its holdings in Silence Therapeutics by 83.8% during the 4th quarter. Barclays PLC now owns 6,126 shares of the company's stock valued at $42,000 after buying an additional 2,793 shares during the last quarter. Finally, Walleye Capital LLC purchased a new position in Silence Therapeutics during the fourth quarter worth $250,000. 98.73% of the stock is owned by institutional investors and hedge funds.

Silence Therapeutics Price Performance

NASDAQ:SLN opened at $5.44 on Friday. The company has a market capitalization of $162.82 million, a P/E ratio of -3.46 and a beta of 1.41. The business has a fifty day simple moving average of $3.86 and a two-hundred day simple moving average of $5.02. Silence Therapeutics has a 1 year low of $1.97 and a 1 year high of $22.47.

Silence Therapeutics (NASDAQ:SLN - Get Free Report) last issued its quarterly earnings data on Thursday, May 8th. The company reported ($0.60) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.18) by ($0.42). Silence Therapeutics had a negative return on equity of 62.81% and a negative net margin of 342.00%. The company had revenue of $0.14 million for the quarter, compared to analysts' expectations of $3.58 million. As a group, analysts anticipate that Silence Therapeutics will post -1.77 earnings per share for the current year.

About Silence Therapeutics

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.